Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry

OBJECTIVE: Etanercept is commonly used to treat juvenile idiopathic arthritis, including juvenile psoriatic arthritis (JPsA); however, information on etanercept’s safety and effectiveness in clinical practice is limited. We used data from the Childhood Arthritis and Rheumatology Research Alliance (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Correll, Colleen K, Stryker, Scott, Collier, David, Phillips, Thomas A, Dennos, Anne C, Balevic, Stephen J, Beukelman, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230983/
https://www.ncbi.nlm.nih.gov/pubmed/37230760
http://dx.doi.org/10.1136/rmdopen-2022-002943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230983/
https://www.ncbi.nlm.nih.gov/pubmed/37230760
http://dx.doi.org/10.1136/rmdopen-2022-002943

Ejemplares similares